Brown Advisory
BHVN

Brown Advisory’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Brown Advisory’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-752,048
Closed -$114M – 1254
2022
Q3 		$114M Sell
752,048
-19,124
-2% -$2.83M 0.22% 97
2022
Q2 		$112M Sell
771,172
-112,398
-13% -$14.4M 0.21% 101
2022
Q1 		$105M Buy
883,570
+34,691
+4% +$4.33M 0.16% 114
2021
Q4 		$117M Sell
848,879
-184,323
-18% -$23.4M 0.15% 110
2021
Q3 		$144M Sell
1,033,202
-8,163
-0.8% -$1.02M 0.21% 95
2021
Q2 		$101M Buy
1,041,365
+51,677
+5% +$4.19M 0.15% 118
2021
Q1 		$67.6M Buy
989,688
+101,404
+11% +$8.2M 0.12% 148
2020
Q4 		$76.1M Buy
888,284
+28,891
+3% +$2.45M 0.14% 126
2020
Q3 		$55.9M Buy
859,393
+11,374
+1% +$745K 0.12% 130
2020
Q2 		$62M Buy
848,019
+67,578
+9% +$3.6M 0.14% 118
2020
Q1 		$26.6M Buy
780,441
+72,757
+10% +$3.33M 0.08% 174
2019
Q4 		$38.5M Sell
707,684
-382,308
-35% -$18.9M 0.1% 169
2019
Q3 		$45.5M Buy
1,089,992
+81,946
+8% +$3.46M 0.13% 146
2019
Q2 		$44.1M Buy
1,008,046
+380,764
+61% +$21.5M 0.13% 157
2019
Q1 		$32.3M Buy
627,282
+173,873
+38% +$7.51M 0.09% 192
2018
Q4 		$16.8M Buy
+453,409
New +$16.3M 0.06% 251

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Brown Advisory's BHVN Position: Q4 2022 in Review

Brown Advisory sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 752,048 shares — an estimated $114M sold.

Brown Advisory first reported a position in BHVN in Q4 2018 and held it in 16 quarters. The position peaked at $144M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Brown Advisory reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Brown Advisory sold 752,048 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $114M.
  • Brown Advisory first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 16 quarters.
  • Brown Advisory's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $144M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Brown Advisory's 13F filing for Q4 2022, filed 13 Feb 2023.